Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13251404 | 1.00 | CA1 (0.42) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL8194462 | 0.87 | CA1 (0.43) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL8051304 | 0.85 | CA1 (0.43) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL16316031 | 0.78 | CTSK (0.40) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL13251410 | 0.78 | CTSK (0.40) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL8282412 | 0.77 | CA1 (0.45) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL13251928 | 0.77 | CA1 (0.45) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL8280459 | 0.77 | CA1 (0.42) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL13251403 | 0.77 | CA1 (0.42) | CA1CA7CA2CYP2D6CA4 | |
| SCHEMBL8227917 | 0.76 | CTSK (0.40) | CA1CA7CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | SCHERING CORPORATION | 2011-06-23 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | CA1 3693/4885CA7 3889/4885CA2 4115/4885 |
| US-20110150835-A1 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease | TMPRSS15, SPINT2, HPN | CA1 3536/4885CA7 4062/4885CA2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.